Interpace Diagnostics Enters into Agreement with Renowned Integrated Health System
October 04, 2018 06:55 ET
|
Interpace Diagnostics Group, Inc.
Agreement with Piedmont Healthcare Covers Company’s Pancreatic Cancer Test PARSIPPANY, NJ, Oct. 04, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group (NASDAQ: IDXG) reported today that it has...
Interpace Diagnostics to Present New Data at the 88th Annual Meeting of the American Thyroid Association (ATA) on October 5th
October 01, 2018 06:55 ET
|
Interpace Diagnostics Group, Inc.
ThyGenX® and ThyraMIR® Data from Clinical Experience Study to be Featured at ATA Product Expo PARSIPPANY, NJ, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG)...
Interpace Diagnostics Announces Reimbursement Expansion of ThyGeNEXT™
September 24, 2018 06:55 ET
|
Interpace Diagnostics Group, Inc.
State of Pennsylvania and New York Approve Commercialization of New Thyroid Cancer Test PARSIPPANY, NJ, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (IDXG), announced...
INTERPACE DIAGNOSTICS ANNOUNCES PARTICIPATION AT THE 20TH ANNUAL GLOBAL INVESTMENT CONFERENCE SPONSORED BY H.C.WAINWRIGHT & CO.
August 27, 2018 08:30 ET
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, Aug. 27, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (“Interpace” or “the Company”), a fully integrated commercial and bioinformatics company that...